首页> 外文期刊>Nanoscale >Reprogramming of the tumor microenvironment using a PCN-224@IrNCs/D-Arg nanoplatform for the synergistic PDT, NO, and radiosensitization therapy of breast cancer and improving anti-tumor immunity
【24h】

Reprogramming of the tumor microenvironment using a PCN-224@IrNCs/D-Arg nanoplatform for the synergistic PDT, NO, and radiosensitization therapy of breast cancer and improving anti-tumor immunity

机译:Reprogramming of the tumor microenvironment using a PCN-224@IrNCs/D-Arg nanoplatform for the synergistic PDT, NO, and radiosensitization therapy of breast cancer and improving anti-tumor immunity

获取原文
获取原文并翻译 | 示例
           

摘要

The low X-ray attenuation coefficient of tumor soft tissue and the hypoxic tumor microenvironment (TME) during radiation therapy (RT) of breast cancer result in RT resistance and thus reduced therapeutic efficacy. In addition, immunosuppression induced by the TME severely limits the antitumor immunity of radiation therapy. In this paper, we propose a PCN-224@IrNCs/D-Arg nanoplatform for the synergistic radiosensitization, photodynamic, and NO therapy of breast cancer that also boosts antitumor immunity (PCN = porous coordination network, IrNCs = iridium nanocrystals, D-Arg = D-arginine). The local tumors can be selectively ablated via reprogramming the tumor microenvironment (TME), photodynamic therapy (PDT) and NO therapy, and the presence of the high-Z element Ir that sensitizes radiotherapy. The synergistic execution of these treatment modalities also resulted in adapted antitumor immune response. The intrinsic immunomodulatory effects of the nanoplatform also repolarize macrophages toward the M1 phenotype and induce dendritic cell maturation, activating antitumor T cells to induce immunogenic cell death as demonstrated in vitro and in vivo. The nanocomposite design reported herein represents a new regimen for the treatment of breast cancer through TME reprogramming to exert a synergistic effect for effective cancer therapy and antitumor immunity.
机译:肿瘤的x射线的衰减系数低软组织肿瘤缺氧放疗期间微环境(时间)(RT)的乳腺癌导致RT阻力和从而降低治疗效果。时间严重免疫抑制诱导限制了抗肿瘤免疫的辐射治疗。pcn - 224 @irncs / D-Arg nanoplatform的协同放射线增减、光能和没有治疗的乳腺癌也增加抗肿瘤免疫(PCN =多孔协调网络,IrNCs =铱纳米晶体,D-Arg =D-arginine)。通过改变肿瘤切除微环境(时间),光动力治疗(PDT)和没有治疗,的存在高红移元素红外放疗处于敏感状态。这些治疗的协同执行模式也导致了抗肿瘤免疫反应。nanoplatform也再极化的影响巨噬细胞M1表型和诱导树突状细胞成熟,激活抗肿瘤T细胞诱导免疫原性细胞死亡证明在体外和体内。纳米复合材料设计在此代表一个报道乳腺癌的治疗的新方案通过时间重组发挥协同为有效的癌症治疗和抗肿瘤效应免疫力。

著录项

  • 来源
    《Nanoscale》 |2023年第25期|10715-10729|共15页
  • 作者单位

    NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, People’s Republic of China.;

    Department of Dermatology, Zhujiang Hospital of Southern Medical University, No. 253 Gongye Avenue, Guangzhou 510091, People’s Republic of China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 分子物理学、原子物理学;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号